AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Reckitt Benckiser Group plc
Video analysis: RBGLY
All videosNo video analysis for this stock yet. Request one from our team.
News: RBGLY
Reckitt Benckiser Group plc (RBGLY) Presents at Barclays 19th Annual Global Consumer Staples Conference Transcript
Reckitt Benckiser Group plc (RBGLY) Presents at Barclays 19th Annual Global Consumer Staples Conference Transcript
Reckitt Benckiser shares rise over 4% as JP Morgan upgrades to 'overweight'
Shares in Reckitt Benckiser Group PLC (LSE:RKT, OTCQX:RBGLY), the consumer goods company behind Dettol and Nurofen, rose over 4% on Tuesday as investors digested a legal win for its Mead Johnson unit and a JP Morgan upgrade to overweight. The upgrade came in a wider note on European consumer staples published by JP Morgan analyst Celine Pannuti on Tuesday.
3 Cheap International Stocks to Buy
These stocks have economic moats and look attractive today.
First Bellwether Trial Today Against Reckitt Benckiser's Mead Johnson in NEC Baby Formula MDL Led by Levin Papantonio
PENSACOLA, Fla.--(BUSINESS WIRE)--Reckitt Benckiser (LON: RKT) subsidiary, Mead Johnson is facing the first bellwether today as part of a multidistrict litigation (MDL) in the US District Court for the Northern District of Illinois over its infant formula Enfamil being linked to necrotizing enterocolitis (NEC) in a premature infant. Inman v. Mead Johnson & Company, LLC, et al. is the first case against Mead Johnson in the MDL to proceed to trial. NEC is a severe intestinal disease that can.
Reckitt Benckiser: Core Brands Remain Undervalued Despite Mead Johnson Litigation Risk
I rate Reckitt Benckiser a buy with a 12–24 month horizon and medium confidence, citing a 21% discount to peer multiples despite litigation overhang. Core Reckitt delivers high-margin, volume-led growth, with FY2025 organic growth of +5.2% and a 26.7% adjusted operating margin, supporting quality business status. Mead Johnson litigation risk remains the key discount driver; recent favorable legal outcomes improve sentiment but do not resolve federal MDL exposure.
Reckitt Benckiser Group: A Solid Quarter Supports The Investment Case
Reckitt delivered solid H1 results, with top line growth in both Core Reckitt and Mead Johnson Nutrition, despite regional disparities. RBGLY's operating profit, margin, and cash flow fell, mainly due to the Essential Home divestment, but management remains confident about forward momentum. The interim dividend grew 5% to 88.6p, yielding 4.2%, and a new £500m buyback was announced, signaling ongoing capital returns.
Reckitt Benckiser Group plc (RBGLY) Q2 2026 Earnings Call Transcript
Reckitt Benckiser Group plc (RBGLY) Q2 2026 Earnings Call Transcript
Reckitt Benckiser Group H1 Earnings Call Highlights
Reckitt Benckiser Group LON: RKT reported accelerating sales growth in the second quarter of 2026, supported by innovation, emerging-market demand and a return to growth in North America, while maintaining its full-year outlook despite commodity and supply-chain volatility.
